GGrantIndex
← Search

ACTG A5127: TREATMENT OF LAMIVUDINE-RESISTANT HBV/HIV CO-INFECTED SUBJECTS

$14,250M01FY2004RRNIH

New York University School Of Medicine, New York NY

Investigators

Linked publications & trials

View original record on NIH RePORTER →